Based on BOT successfully completing a Phase 1b study of BTX 1503 during 1Q CY2018 with the results above, I reckon the chances of the The Phase 2 clinical trial being a success are extraordinarily high.
Up your BOT
Not advice, DYOR
LEAD PRODUCT: BTX 1503 (MODERATE TO SEVERE ACNE) - Phase 2 clinical trial
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
0.015(5.56%) |
Mkt cap ! $448.9M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 29.5¢ | 27.0¢ | $1.789M | 6.392M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29995 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 6507 | 1 |
View Market Depth
| Last trade - 16.10pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
29.0¢ |
Change
0.015 ( 7.41 %) |
||||
| Open | High | Low | Volume | ||
| 27.5¢ | 29.5¢ | 27.0¢ | 1370780 | ||
| Last updated 15.59pm 20/05/2024 ? | |||||
| BOT (ASX) Chart |